Catheter Ablation for Atrial Arrhythmias in Patients With Cardiac Amyloidosis.

Catheter Ablation for Atrial Arrhythmias in Patients With CA Background Cardiac amyloidosis (CA) is associated with increased atrial arrhythmias risk. The efficacy/safety of catheter-based ablation therapy in patients with CA has not been adequately assessed. Methods and Results All diagnosed CA pat...

Descripción completa

Detalles Bibliográficos
Publicado en:Journal of Cardiovascular Electrophysiology Vol. 27; no. 10; pp. 1167 - 1174
Autores principales: TAN, NICHOLAS Y., MOHSIN, YOUSEF, HODGE, DAVID O., LACY, MARTHA Q., PACKER, DOUGLAS L., DISPENZIERI, ANGELA, GROGAN, MARTHA, ASIRVATHAM, SAMUEL J., MADHAVAN, MALINI, McLEOD, CHRISTOPHER J.
Formato: research tables/charts Journal Article
Publicado: Wiley-Blackwell Oct2016
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=118833276&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 118833276
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        10453873
        GSB
      jtl: Journal of Cardiovascular Electrophysiology
      issn: 10453873
      maglogo: Y
    pubinfo:
      dt: Oct2016
      vid: 27
      iid: 10
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        118833276
        118833276
        118833276
        10.1111/jce.13046
        118833276
      ppf: 1167
      ppct: 7
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Catheter Ablation for Atrial Arrhythmias in Patients With Cardiac Amyloidosis.
      aug:
        au:
          TAN, NICHOLAS Y.
          MOHSIN, YOUSEF
          HODGE, DAVID O.
          LACY, MARTHA Q.
          PACKER, DOUGLAS L.
          DISPENZIERI, ANGELA
          GROGAN, MARTHA
          ASIRVATHAM, SAMUEL J.
          MADHAVAN, MALINI
          McLEOD, CHRISTOPHER J.
        affil: Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester Minnesota
      sug:
        subj:
          Amyloidosis, Cardiac Complications
          Catheter Ablation
          Arrhythmia, Atrial Therapy
          Treatment Outcomes
          Recurrence
          Serum Albumin Blood
          Human
          Female
          Male
          Chi Square Test
          Kaplan-Meier Estimator
          P-Value
          Retrospective Design
          Inpatients
          Academic Medical Centers United States
          United States
          Arrhythmia, Atrial Symptoms
          Arrhythmia, Atrial Mortality
          Middle Age
          Aged
          Middle Aged: 45-64 years
          Aged: 65+ years
          Female
          Male
      ab: Catheter Ablation for Atrial Arrhythmias in Patients With CA Background Cardiac amyloidosis (CA) is associated with increased atrial arrhythmias risk. The efficacy/safety of catheter-based ablation therapy in patients with CA has not been adequately assessed. Methods and Results All diagnosed CA patients who underwent atrial arrhythmia ablation therapy from 1995 to 2015 were reviewed. Arrhythmia recurrence, NYHA symptoms, and mortality were recorded. A total of 26 patients with CA and atrial arrhythmias were included; there were 7 light-chain (AL), 17 wild-type transthyretin (ATTRwt), and 2 mutated transthyretin (ATTRm) amyloidosis patients in total. Of which 13 underwent atrial arrhythmia ablation (CA-A) and 13 underwent AV nodal ablation (CA-AVN). In the CA-A group, there were: 3 with atrial fibrillation (AF); 6 with atrial flutter (AFL); 2 with AF/AFL; and 2 with atrial tachycardia (AT). One-year and 3-year recurrence-free survival were 75% and 60%, respectively. NYHA symptom improvement 6 months postablation was observed in both CA-A and CA-AVN groups: 7/10 (70%) and 4/8 (50%), respectively. Eleven patients with CA died (8 in CA-AVN group vs. 3 in CA-A group). Conclusions Catheter-based ablation for patients with CA appears to provide important symptomatic relief. However, mortality from the underlying disease remains a significant issue for the amyloid light-chain subtype.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N